Smiths Medical and Ivenix Partner to Revolutionize Infusion Management

  • Minneapolis and Boston, May 4th, 2021 – Smiths Medical, a global medical device leader, today announced it has formed an exclusive partnership with Ivenix, Inc. that positions the companies as the first in the U.S. to offer a comprehensive suite of infusion management solutions to meet healthcare needs across the continuum of care. The long-term partnership, which includes a strategic investment from Smiths Medical, unites two innovators under a common goal of revolutionizing infusion management to improve patient safety and meet the needs of healthcare providers today and into the future…READ MORE

Lundbeck to acquire Abide Therapeutics, adding a unique discovery platform and a lead compound in an exploratory phase IIa program for Tourette’s

  • Abide’s world-class discovery platform is focused on harnessing the therapeutic potential of one of the largest and most diverse enzyme classes – the serine hydrolases (SHs) – with the potential to deliver unprecedented compounds across a broad range of central nervous system (CNS) indications
  • Abide’s lead product ABX 1431 is a first-in-class inhibitor of monoacylglycerol lipase (MGLL), modulating the endocannabinoid system. ABX-1431 is in clinical development for Tourette’s  (exploratory phase IIa) and neuropathic pain (phase I)
  • Lundbeck to acquire Abide for USD 250 million in upfront payment and with additional development and sales milestones

Valby, Denmark, San Diego, USA, 6 May 2019 – H. Lundbeck A/S (Lundbeck) and Abide Therapeutics, Inc. (Abide) today announced signing of a definitive agreement in which Lundbeck LLC has agreed to acquire Abide. Under the terms of the agreement, Lundbeck may pay USD 250 million (approximately DKK 1.65 billion) upfront with a commitment to pay future development and sales milestones to the group of current owners of up to USD 150 million (approximately DKK 1 billion). This acquisition provides Lundbeck a novel discovery platform and a U.S.-based research hub…READ MORE

double exposure image of virtual human 3dillustration on blue circuit board background represent artificial 
intelligence AI technology

Prealize Wins MedTech Breakthrough Innovation Award for Second Consecutive Year

PALO ALTO, Calif.April 29, 2020 /PRNewswire/ — Prealize, an artificial intelligence (AI)-enabled health insights company, today announced that, for the second straight year, it was selected as a winner of the Innovation in Healthcare Analytics Award, presented as part of the 2020 MedTech Breakthrough Awards program. In its fourth year, this program recognizes top companies, people, platforms and products in the health, fitness and medical technology industries today.

Prealize, which was known as Cardinal Analytx Solutions until it rebranded in January 2020, supports delivery of proactive healthcare by leveraging the power of AI and machine learning (ML) to identify not only patients at rising risk of health changes, but also the timing and key drivers of that risk.. READ MORE


Teladoc Health Launches “myStrength Complete” As First Unified Mental Health Care Experience

New Consumer Study Reinforces Impact of Comprehensive Virtual Mental Health Care

PURCHASE, NY May 11, 2021 — Teladoc Health, Inc. (NYSE: TDOC) today announced the launch of myStrength Complete, an integrated mental health service providing personalized, targeted care to consumers in a single, comprehensive experience. The announcement comes as more than half of people with mental health concerns report that they do not know where to start when getting care, highlighting the importance of the digital front door myStrength Complete will provide.READ MORE


Consumers Will Enter the Health Care System in Different Ways

While COVID-19 has greatly impacted how consumers access health care so far this year, the news of multiple vaccines on the horizon bring with them expectations that patients will return. Sapphire’s CEO, Kyle Raffaniello, recently spoke with roi-nj.com about how consumers will have new priorities post-pandemic when it comes to health care decisions….READ MORE

Vividion Therapeutics Expands Leadership Team with Key Regulatory and CMC

SAN DIEGO – April 20, 2021 – Vividion Therapeutics, Inc., a biopharmaceutical company utilizing novel discovery technologies to unlock high value, traditionally undruggable targets with precision therapeutics for devastating cancers and immune disorders, today announced that Xiaohu Deng, Ph.D., has been appointed as head of technical operations and Lisa Percival has been appointed as head of regulatory…READ MORE


Privia Health Announces Closing of Initial Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares

ARLINGTON, VA.- May 3, 2021– Privia Health Group, Inc. (“Privia Health”) (Nasdaq: PRVA), a technology-driven, national physician enablement company that collaborates with medical groups, health plans and health systems, announced the closing of its initial public offering of 22,425,000 shares of its common stock at a public offering price of $23.00 per share. The offering consisted of 5,725,000 shares of common stock offered by Privia Health and 16,700,000 shares of common stock sold by Privia Health’s majority stockholder…READ MORE

Scroll to top